Biomedicines,
Journal Year:
2025,
Volume and Issue:
13(1), P. 133 - 133
Published: Jan. 8, 2025
Glioblastoma
is
one
of
the
most
aggressive
brain
cancers,
characterized
by
active
infiltrative
growth
and
high
resistance
to
radiotherapy
chemotherapy.
Sesquiterpene
triterpenoids
(STLs)
their
semi-synthetic
analogs
are
considered
as
a
promising
source
novel
anti-tumor
agents
due
low
systemic
toxicity
multi-target
pharmacological
effects
on
key
processes
associated
with
tumor
progression.
The
current
review
aims
systematize
knowledge
anti-glioblastoma
potential
STLs
accumulated
over
last
decade
identify
in
glioblastoma
cells
that
susceptible
action
STLs.
An
analysis
published
data
clearly
demonstrated
STLs,
which
can
successfully
cross
blood-brain
barrier,
exert
complex
inhibitory
effect
through
induction
"mitochondrial
dysfunction-oxidative
stress-apoptosis"
axis,
inhibition
glucose
metabolism
cell
cycle
phase
transition,
suppression
motility
invasion
blockade
proneural-mesenchymal
transition.
Taken
together,
this
highlights
not
only
able
induce
death,
but
also
effectively
affect
diffusive
spread,
suggests
possible
directions
for
further
investigation
context
better
understand
mechanism
action.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(5), P. 2529 - 2529
Published: Feb. 21, 2024
Glioblastoma
(GB)
stands
out
as
the
most
prevalent
and
lethal
form
of
brain
cancer.
Although
great
efforts
have
been
made
by
clinicians
researchers,
no
significant
improvement
in
survival
has
achieved
since
Stupp
protocol
became
standard
care
(SOC)
2005.
Despite
multimodality
treatments,
recurrence
is
almost
universal
with
rates
under
2
years
after
diagnosis.
Here,
we
discuss
recent
progress
our
understanding
GB
pathophysiology,
particular,
importance
glioma
stem
cells
(GSCs),
tumor
microenvironment
conditions,
epigenetic
mechanisms
involved
growth,
aggressiveness
recurrence.
The
discussion
on
therapeutic
strategies
first
covers
SOC
treatment
targeted
therapies
that
shown
to
interfere
different
signaling
pathways
(pRB/CDK4/RB1/P16
Bioconjugate Chemistry,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 12, 2025
Brain
tumors,
particularly
glioblastomas,
represent
the
most
complicated
cancers
to
treat
and
manage
due
their
highly
invasive
nature
protective
barriers
of
brain,
including
blood-brain
barrier
(BBB).
The
efficacy
currently
available
treatments,
viz.,
radiotherapy,
chemotherapy,
immunotherapy,
are
frequently
limited
by
major
side
effects,
drug
resistance,
restricted
penetration
into
brain.
Lipid
nanoparticles
(LNPs)
have
emerged
as
a
promising
targeted
delivery
system
for
brain
tumors.
nanocarriers
gained
tremendous
attention
tumor
therapeutics
multiple
encapsulation
abilities,
controlled
release,
better
biocompatibility,
ability
cross
BBB.
Herein,
detailed
analysis
design,
mechanisms,
therapeutic
benefits
LNPs
in
treatment
is
discussed.
Moreover,
we
also
discuss
safety
issues
clinical
developments
current
future
challenges.
Further,
focused
on
transformation
therapy
eliminating
effects
engineering
overcome
related
biological
barriers,
which
provide
personalized,
affordable,
low-risk
options.
International Journal of Molecular Sciences,
Journal Year:
2024,
Volume and Issue:
25(11), P. 5774 - 5774
Published: May 26, 2024
Glioblastoma
is
the
most
common
malignant
primary
brain
tumor
in
adult
population,
with
an
average
survival
of
12.1
to
14.6
months.
The
standard
treatment,
combining
surgery,
radiotherapy,
and
chemotherapy,
not
as
efficient
we
would
like.
However,
current
possibilities
are
no
longer
limited
therapies
due
rapid
advancements
biotechnology.
New
methods
enable
a
more
precise
approach
by
targeting
individual
cells
antigens
overcome
cancer.
For
treatment
glioblastoma,
these
gamma
knife
therapy,
proton
beam
tumor-treating
fields,
EGFR
VEGF
inhibitors,
multiple
RTKs
PI3K
pathway
inhibitors.
In
addition,
increasing
understanding
role
immune
system
tumorigenesis
ability
identify
tumor-specific
helped
develop
immunotherapies
GBM
cells,
including
CAR-T,
CAR-NK
dendritic
checkpoint
Each
described
has
its
advantages
disadvantages
faces
problems,
such
inefficient
crossing
blood-brain
barrier,
various
neurological
systemic
side
effects,
escape
mechanism
tumor.
This
work
aims
present
modern
treatments
glioblastoma.
ACS Chemical Neuroscience,
Journal Year:
2025,
Volume and Issue:
unknown
Published: Feb. 25, 2025
Glioblastoma
multiforme
(GBM)
is
a
highly
aggressive
brain
cancer
with
median
survival
of
15
months.
Despite
advancements
in
conventional
treatment
approaches
such
as
surgery
and
chemotherapy,
the
prognosis
remains
poor.
This
study
investigates
use
rapid
evaporative
ionization
mass
spectrometry
(REIMS)
for
real-time
overall
time
classification
GBM
samples
uses
matrix-assisted
laser
desorption
imaging
(MALDI-MSI)
to
compare
lipidomic
differences
within
tumors.
A
total
45
biopsies
were
analyzed
develop
prediction
model
IDH-wild
type
GBM.
REIMS
patterns
from
28
patients
classified
97.7%
correct
rate,
identifying
key
discriminators
between
short-term
(0–12
months)
prolonged
(>12
survivors.
Cross-validation
additional
showed
that
correctly
66.7
69.4%
accuracy,
respectively.
MALDI-MSI
was
performed
confirm
derived
data.
Results
indicated
42
33
discriminating
features
survival,
Proteomic
profiling
by
isolating
tumor
regions
via
laser-capture
microdissection
(LMD)
liquid
chromatography-tandem
(LC-MS/MS).
Subsequently,
1387
proteins
identified,
which
79
significantly
altered.
In
conclusion,
this
shows
rapidly
predicts
glioblastoma
times
based
on
profiles
during
electrosurgical
dissection.
confirmed
these
specific
region
sections.
LMD-guided
LC-MS/MS-based
proteomics
revealed
altered
pathways
survival.
research,
including
comprehensive
predictive
GBM,
could
guide
resection
surgeries
accurate
tissue
identification
well
provide
insights
into
mechanisms,
possibly
related
therapy
response.
International Journal of Molecular Sciences,
Journal Year:
2023,
Volume and Issue:
24(18), P. 14044 - 14044
Published: Sept. 13, 2023
Alzheimer’s
disease
(AD)
is
a
progressive
neurodegenerative
that
affects
most
people
worldwide.
AD
complex
central
nervous
system
disorder.
Several
drugs
have
been
designed
to
cure
AD,
but
with
low
success
rates.
Because
the
blood–brain
and
blood–cerebrospinal
fluid
barriers
are
two
protect
system,
their
presence
has
severely
restricted
efficacy
of
many
treatments
studied
for
diagnosis
and/or
therapy.
The
use
nanoparticles
treatment
focus
an
established
rapidly
developing
field
nanomedicine.
Recent
developments
in
nanomedicine
made
it
possible
effectively
transport
brain.
However,
numerous
obstacles
remain
successful
nanomedicines
clinical
settings
treatment.
Furthermore,
given
rapid
advancement
therapeutics,
better
outcomes
patients
can
be
anticipated.
This
article
provides
overview
recent
using
different
types
management
AD.
Genes and Immunity,
Journal Year:
2024,
Volume and Issue:
25(3), P. 201 - 208
Published: May 3, 2024
Glioblastoma
(GBM)
is
the
most
common
and
aggressive
malignant
primary
brain
tumor
in
adults.
Current
treatment
options
for
GBM
include
surgical
resection,
radiation,
chemotherapy,
which
predominantly
slow
cancer
growth
reduce
symptoms,
resulting
a
5-year
survival
rate
of
no
more
than
10%.
Chimeric
antigen
receptor
(CAR)
T-cell
therapy
new
class
cellular
immunotherapy
that
has
made
great
progress
treating
tumors.
Human
epidermal
factor
2
(HER2)
overexpressed
may
provide
potential
therapeutic
target
treatment.
In
this
study,
we
constructed
third-generation
CAR-T
cells
targeting
HER2
GBM.
HER2-CAR-T
showed
effective
anti-tumor
activity
both
vitro
vivo.
Furthermore,
HER2-specific
exhibited
strong
cytotoxicity
cytokine-secreting
abilities
against
vitro.
Anti-HER2
also
increased
with
increasing
effector-to-target
ratios.
delivered
via
peritumoral
injection
successfully
stunted
progression
Moreover,
intravenous
administration
anti-HER2
resulted
improvement
compared
administration.
conclusion,
our
study
shows
represent
an
emerging
